高 JAK2 蛋白表达预示可切除胰腺导管腺癌患者预后不良。
High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
机构信息
Department of Oncology, Shengjing Hospital of China Medical University, 36 Sanhao Road, Shenyang 110004, China.
Department of Pathology, Shengjing Hospital of China Medical University, 36 Sanhao Road, Shenyang 110004, China.
出版信息
Dis Markers. 2020 Sep 21;2020:7656031. doi: 10.1155/2020/7656031. eCollection 2020.
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies worldwide. The JAK/STAT signaling pathway is involved in pancreatic cancer tumorigenesis. However, the prognostic value of JAK2 expression in resectable PDAC is unclear.
METHOD
In this study, we performed a clinicopathological analysis of 62 resectable PDAC cases with a primary focus on survival. JAK2 expression was examined by immunohistochemistry. The relationship between JAK2 expression and clinicopathological features and prognosis was analyzed.
RESULTS
Survival curve analyses revealed that high levels of JAK2 expression predict a poor prognosis in resectable PDAC patients. Multivariate analysis confirmed that JAK2 expression can predict the prognosis of PDAC.
CONCLUSIONS
Assessment of JAK2 protein expression may be a promising method to predict prognosis in patients with resectable PDAC.
背景
胰腺导管腺癌 (PDAC) 是全球最致命的恶性肿瘤之一。JAK/STAT 信号通路参与胰腺癌的发生。然而，JAK2 表达在可切除 PDAC 中的预后价值尚不清楚。
方法
本研究对 62 例可切除 PDAC 病例进行了临床病理分析，主要关注生存情况。采用免疫组织化学法检测 JAK2 表达。分析 JAK2 表达与临床病理特征和预后的关系。
结果
生存曲线分析显示，JAK2 表达水平高提示可切除 PDAC 患者预后不良。多因素分析证实 JAK2 表达可预测 PDAC 的预后。
结论
评估 JAK2 蛋白表达可能是预测可切除 PDAC 患者预后的一种有前途的方法。
Zotero 插件